HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT)
HC Wainwright has revised its Q3 2026 earnings per share estimates for Altimmune (NASDAQ:ALT) to a loss of $0.13, an improvement from its prior estimate of $0.15. The firm also updated its full-year and multi-year forecasts, expecting the company to remain unprofitable through 2030, though with reduced projected losses. Altimmune recently surpassed consensus estimates for its latest quarter, reporting a loss of $0.12 per share against an expected $0.14 loss.
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Altimmune (ALT) has a growing cash position, now at $519 million, which is expected to fund operations into 2029 and support its phase III MASH program and phase II ALD study. The company's valuation reflects its reliance on the single experimental drug, pemvidutide, for various metabolic conditions, but it faces significant execution, competitive, and long-term funding risks, leading to a Zacks Rank #3 (Hold) despite its improved cash runway.
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating for Altimmune (ALT.US), maintaining a target price of $20. This indicates the firm's continued confidence in the company's stock performance.
Altimmune Stock Price Forecast. Should You Buy ALT?
Altimmune, Inc. (ALT) is currently rated as a "Sell Candidate" by StockInvest.us, despite a recent 2.08% gain. The stock shows both buy signals from a pivot bottom and MACD, alongside sell signals from short and long-term Moving Averages, indicating mixed short-term prospects. With a projected 5.38% rise over the next three months, the analysis suggests a negative evaluation for the stock in the immediate future.
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares
Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the past year, signaling strong confidence from leadership in the company's future, particularly its focus on obesity and liver disease treatments. The purchase, valued at $44,250, suggests insiders believe the stock is undervalued despite the risks inherent in a clinical-stage biopharmaceutical company.
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each
Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form 4 filing indicates the purchase was not made under a Rule 10b5-1 trading plan.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune (ALT) reported a Q2 2026 loss of 12 cents per share, which was narrower than the Zacks Consensus Estimate of 15 cents. The company's lead candidate, Pemvidutide, a dual glucagon/GLP-1 receptor agonist, is progressing through late-stage clinical trials for MASH, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Altimmune expects its cash reserves to fund operations until 2029.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune (ALT) reported a narrower-than-expected loss of 12 cents per share in Q2 2026, beating the Zacks Consensus Estimate of 15 cents. The company, which currently has no marketed drugs, focused on advancing its lead candidate, pemvidutide, with ongoing clinical studies for MASH, AUD, and ALD, and expects its cash runway to extend into 2029. Shares of ALT have declined by 18.9% year-to-date.
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary
Altimmune, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(22.83M), with diluted loss per share at $(0.12). This represents an improvement in EPS compared to $(0.27) in Q2 2025. Key business highlights include the start of the PERFORMA Phase 3 MASH trial, positive IMPACT MASH data, successful RECLAIM Phase 2 AUD results, and a headquarters relocation to Morristown, NJ.
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
Dimensional Fund Advisors LP significantly increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares to own a total of 1.05 million shares valued at $3.22 million. Other institutional investors also adjusted their positions in Altimmune, which currently has 78.05% institutional ownership. Despite recent stock performance near its 52-week low and ongoing negative profitability, analysts maintain a "Moderate Buy" rating with a consensus price target of $14.33.
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results
Altimmune Inc (ALT) reported Q2 '26 earnings with an EPS of -$0.12, beating the estimated -$0.14 by 11.44%. The company achieved significant clinical milestones, including initiating a Phase 3 MASH trial and positive Phase 2 results in AUD, while also advancing enrollment for its ALD development program. However, Altimmune experienced an increased net loss and higher research and development expenses during the quarter.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune announced its Q2 2026 financial results, highlighting key progress in its clinical programs for pemvidutide. The company initiated a global Phase 3 trial for MASH, reported positive topline data from a Phase 2 AUD trial, and completed enrollment for a Phase 2 ALD trial. Altimmune reported $519 million in cash and cash equivalents, with a net loss of $22.8 million for the quarter.
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Altimmune (NASDAQ:ALT) reported quarterly earnings, beating analyst expectations with a loss of $0.12 per share against an anticipated loss of $0.14. The company announced progress in its pemvidutide programs, including the start of the Phase III MASH trial and positive results from the Phase II alcohol use disorder study. Altimmune holds approximately $519 million in cash, sufficient to fund the MASH trial's 52-week readout, and plans to seek non-dilutive financing for potential future programs.
William Blair Maintains Altimmune(ALT.US) With Hold Rating
William Blair has reiterated its Hold rating on Altimmune (ALT.US). This indicates that the analyst firm recommends investors maintain their current position in the stock, without suggesting buying more or selling. The article does not provide specific reasons or financial data behind this rating.
Altimmune Releases Q2 2026 Financial Results
Altimmune, Inc. (ALT) announced its Q2 2026 financial results, reporting a narrower basic and diluted loss of $0.12 per share compared to the -$0.14 expected loss. The company posted $0 in revenue for the quarter, a 100% decrease from Q2 2025, and a net loss of $22.8 million. Wall Street analysts currently rate Altimmune with 9 buy, 2 hold, and 0 sell recommendations.
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise
Altimmune reported a narrower-than-expected Q2 2026 loss of $0.12 per share, beating analyst estimates, as the biotech advanced late-stage trials for liver disease and alcohol use disorder. The company's shares rose 3.87% following the announcement. Altimmune highlighted a strong cash position of $519 million, sufficient to fund operations through the 2029 MASH data readout, and positive phase II data from its alcohol use disorder study, RECLAIM.
Altimmune Q2 Earnings Call Highlights
Altimmune has initiated patient enrollment for its Phase III PERFORMA trial of pemvidutide for MASH and is advancing plans for later-stage development in AUD. The company reported positive topline results from its Phase II RECLAIM trial in AUD and completed enrollment for the Phase II RESTORE trial in ALD. Altimmune ended Q2 with $519 million in cash, which is expected to fund operations through the PERFORMA 52-week data readout in 2029, with a preference for non-dilutive financing for a potential Phase III AUD trial.
Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs
Altimmune reported a net loss of $22.8 million and held $519 million in cash for Q2 2026. The company highlighted significant progress in its pemvidutide programs, including the initiation of the PERFORMA Phase 3 MASH trial, positive topline results from the RECLAIM Phase 2 AUD trial, and completion of enrollment for the RESTORE Phase 2 ALD trial. Altimmune also completed a public offering raising $225 million and plans to relocate its headquarters.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune, Inc. announced its second-quarter 2026 financial results, highlighting key milestones including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial. The company also completed patient enrollment for the RESTORE Phase 2 ALD trial, demonstrating progress in its pemvidutide development for serious liver diseases. Financially, Altimmune reported $519 million in cash, cash equivalents, and investments as of June 30, 2026, with a net loss of $22.8 million for the quarter.
Altimmune, Inc. (ALT) options chain – Yahoo Finance
This article displays the options chain for Altimmune, Inc. (ALT) as of August 7, 2026. It includes detailed call and put option data such as strike prices, last prices, changes, volume, and open interest for August 21, 2026, expiry. The current stock price and related tickers are also provided.
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune, Inc. (Nasdaq: ALT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results and update, which will also be webcast live on the company's Investor Relations website. Altimmune is a biopharmaceutical company developing pemvidutide for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
Altimmune to discuss its liver-treatment candidate Aug. 12
Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, including a conference call and webcast at 8:30 a.m. ET to review results and provide a business update. The company is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases such as MASH, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Following this announcement, Altimmune's stock (ALT) saw a mild negative market reaction, declining by 1.65%.
Altimmune (ALT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALT
This article provides a comprehensive overview of Altimmune's FDA-related activities for its drug pemvidutide, detailing clinical trial updates, regulatory submissions, and designations through 2026. Pemvidutide is being developed for conditions including obesity, MASH (metabolic dysfunction-associated steatohepatitis),
Altimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan
Altimmune, Inc. (ALT) CFO Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026, through the company's 2019 Employee Stock Purchase Plan (ESPP). The shares were purchased at $2.414 each, representing 85% of the closing price on that day, for the ESPP period from February 1 to July 31, 2026. Following this transaction, Weaver directly holds 39,831 shares of Altimmune common stock.
Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash
Altimmune has announced the initiation of its PERFORMA Phase 3 trial for pemvidutide. This trial focuses on evaluating the drug's efficacy in patients diagnosed with MASH (Metabolic Dysfunction-Associated Steatohepatitis). The information was released via Reuters and is available on TradingView.
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Altimmune has begun enrolling patients in its global PERFORMA Phase 3 trial for pemvidutide, a dual glucagon/GLP-1 receptor agonist, to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. The trial aims to evaluate the drug's efficacy and safety, with primary endpoints including fibrosis improvement and MASH resolution, following positive results from the IMPACT Phase 2b study. Anticipating 52-week data in 2029, this milestone advances Altimmune's lead program, which has also received FDA Fast Track and Breakthrough Therapy Designations for MASH.
Altimmune Inc Today's Market Trends | ALT Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey
This article provides a detailed analysis of Altimmune Inc (ALT) stock, highlighting its market trends, real-time quotes, and trading strategies. It covers key financial figures, institutional ownership, analyst ratings, and the company's biopharmaceutical pipeline, including pemvidutide for obesity and MASH. Despite recent stock performance, the company's fundamentals are considered healthy with high growth potential, and analysts rate it as a Buy with a significant upside.
H.C. Wainwright reiterates Altimmune stock rating on trial results
H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Altimmune (NASDAQ:ALT) following positive Phase 2 trial results for its drug candidate, pemvidutide, in treating alcohol use disorder. The drug met its primary endpoint by significantly reducing heavy drinking days and also achieved FDA-recognized secondary endpoints. Altimmune plans to meet with the FDA regarding alcohol use disorder, complete enrollment for another relevant trial in Q3 2026, and start a Phase 3 trial for metabolic dysfunction-associated steatohepatitis also in Q3 2026.
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript
This article provides the transcript for Altimmune Inc.'s RECLAIM Phase 2 Trial in AUD Topline Results Conference Call held on July 28, 2026. The call began with an introduction by Louis Sine, Vice President of Investor Relations, and detailed how participants could ask questions. It focuses on the topline results of their Phase 2 trial for Alcohol Use Disorder.
Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide
Altimmune's stock surged in premarket trading following positive results from its Phase 2 MOMENTUM trial for pemvidutide, a GLP-1/glucagon receptor dual agonist. The trial met its primary and key secondary endpoints, showing significant weight loss at 48 weeks, with 75% of patients on the highest dose achieving at least 15% weight loss. Pemvidutide also demonstrated favorable safety and tolerability, with low rates of gastrointestinal side effects.
Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication
Altimmune has achieved a significant milestone in treating alcohol use disorder, a field also being explored by major pharmaceutical companies like Eli Lilly and Novo Nordisk. The article highlights Altimmune's efforts to innovate the treatment paradigm for this condition.
Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial
Altimmune's experimental GLP-1 drug, pemvidutide, significantly reduced heavy drinking days in a Phase 2 trial for alcohol use disorder. The drug, which targets both GLP-1 and glucagon receptors, also aims to treat the fatty liver disease MASH and showed a robust clinical profile compared to other treatments. Altimmune plans to discuss the path forward with the FDA for alcohol use disorder and is on track to begin a pivotal Phase 3 trial for MASH.
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune announced positive top-line results from its RECLAIM Phase 2 trial for pemvidutide, showing significant reductions in heavy drinking days and improvements across secondary endpoints for alcohol use disorder. The drug also achieved significant body weight reduction and demonstrated a favorable tolerability profile. Altimmune plans to meet with the FDA to discuss the path forward for pemvidutide in alcohol use disorder.
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
Altimmune's experimental drug pemvidutide successfully met its primary endpoint in a Phase II trial for alcohol use disorder (AUD), significantly reducing heavy drinking days and improving other key measures. The company plans to seek an FDA end-of-Phase-II meeting to discuss moving towards a Phase III registration program. Pemvidutide also demonstrated a statistically significant reduction in body weight and showed exploratory improvements in liver-fibrosis risk.
Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results
Altimmune Inc. (NASDAQ:ALT) shares rose 18% after its Phase 2 RECLAIM study of pemvidutide for alcohol use disorder showed positive results, meeting its primary endpoint with a statistically significant reduction in heavy drinking days. The drug also met key secondary endpoints recognized by the FDA and demonstrated a generally well-tolerated safety profile. Altimmune plans to seek an End-of-Phase 2 meeting with the FDA to discuss further clinical development.
ALT Stock Holds Range As Traders Weigh Cash And Losses
Altimmune Inc. (ALT) stock is consolidating between $2.75 and $3.05 after recent selling pressure, despite a 12.16% surge driven by clinical trial progress. The company boasts a strong balance sheet with $331.5M in cash, providing a long funding runway, but continues to post significant losses, making it a high-risk biotech stock. Traders are closely watching its volatile price action, characterized by sharp premarket spikes and quick profit-taking, recognizing it as a speculative vehicle rather than a value investment.
ALT Stock Holds Range As Cash Runway Supports Speculative Trading
Altimmune Inc. (ALT) stock has been trading up by 11.82%, primarily driven by promising clinical trial progress. Despite recent sideways trading between $2.75 and $3.15, the company has a strong balance sheet with $97.6M in cash and minimal debt, providing a significant runway despite ongoing losses and tiny revenue, making it a high-risk, high-reward development story for traders. Active traders are focused on the $3.00 level as a key indicator for short-term direction, recognizing that its trading behavior is driven by sentiment and chart patterns due to its high cash burn but substantial capital cushion.
Altimmune rises as GLP-1 cuts drinking in mid-stage trial
Altimmune (ALT) shares rose over 15% in premarket trading after its GLP-1 candidate, pemvidutide, demonstrated a reduction in drinking in a mid-stage trial for patients with alcohol use disorder. The biotech company, headquartered in Gaithersburg, Maryland, released topline data from the study.
Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD
Altimmune announced positive topline Phase 2 results for its drug pemvidutide 2.4 mg in treating Alcohol Use Disorder (AUD), demonstrating a significant reduction in heavy drinking days compared to placebo. The RECLAIM study met its primary endpoint and two FDA-recognized secondary endpoints, showing favorable tolerability despite some gastrointestinal side effects. The company plans to engage with the FDA for an End-of-Phase 2 meeting and submit the data for further publication and presentation.
Altimmune stock surges 18% on positive trial results
Altimmune Inc. (NASDAQ:ALT) shares surged 18% after the company announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The trial met its primary and key secondary endpoints, showing a statistically significant reduction in heavy drinking days and favorable results in WHO risk drinking levels and zero heavy drinking days. Altimmune plans to discuss the path forward with the FDA.
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Altimmune, Inc. announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder (AUD). The trial met its primary endpoint, showing a statistically significant reduction in heavy drinking days, and achieved important secondary endpoints recognized by the FDA as registrational. Pemvidutide also demonstrated a generally favorable tolerability profile and a significant reduction in body weight.
Altimmune Inc (ALT) Balance Sheet
This article provides detailed balance sheet data for Altimmune Inc (ALT), allowing users to evaluate its financial health through quarterly and annual figures. It includes key financial metrics like cash and short-term investments, total assets, liabilities, and shareholders' equity, along with supporting FAQs. The data presented covers a wide range of historical quarters and years, offering a comprehensive look at the company's financial evolution.
Altimmune Inc Financials
This article provides a detailed financial summary of Altimmune Inc (ALT), including its latest stock price, market capitalization, and key financial indicators. It presents extensive quarterly and annual data for EPS, Revenue, Net Profit, Balance Sheet items, and Cash Flow, based on reports up to FY2025. The company's stock shows a recent increase, although financial reports highlight negative EPS and Net Profit, alongside significant changes in revenue and assets.
Altimmune Market Sentiment
This article provides an overview of the market sentiment for Altimmune (ALT), including analyst consensus, short interest, options flow, and insider activity. It highlights a strong "Buy" consensus from analysts with ambitious price targets and notes a significant short interest of 24.5%. The article also lists recent analyst actions, including initiations, upgrades, and downgrades, and mentions recent "whale alert" activity in the stock.
ETFs Investing in Altimmune, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Altimmune, Inc. (ALT). It provides a detailed table including each ETF's market value, weight of ALT stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs predominantly focus on healthcare, biotechnology, small-cap, and micro-cap sectors.
Altimmune Inc (ALT) Income Statement
This article provides a detailed quarterly and annual income statement for Altimmune Inc (ALT) from 2012 to 2026, offering insights into its financial performance, including total revenue, operating expenses, and net income. It also includes an FAQ section explaining how to interpret the income statement and key metrics for analyzing ALT stock.
Altimmune Inc (ALT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Altimmune Inc (ALT), indicating its current valuation score is 7.38, ranking 243 out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is noted as -3.00, which is significantly below its recent high and above its recent low. Key valuation metrics like P/E, P/B, P/S, and P/CF are mentioned, but relevant data for P/B, P/S, and P/CF have not been disclosed by the company.
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Altimmune Inc (ALT), detailing its current price momentum score of 3.90, ranking 302 out of 386 in the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $3.20 and a support level of $2.54, suggesting suitability for range-bound swing trading. The analysis includes various technical indicators like MACD, RSI, and moving averages, collectively indicating a "Neutral" signal for the stock.
Altimmune Inc (ALT) Institutional Confidence
The article analyzes the institutional confidence in Altimmune Inc (ALT), noting its current score of 3.00, placing it 192nd out of 386 in its industry. The institutional shareholding proportion is 30.53%, a decrease of 32.53% quarter-over-quarter. Steven Cohen is identified as the largest institutional shareholder, holding 687.92K shares, representing 0.51% of outstanding shares.
Altimmune (FRA:3G0) Selling and Marketing Expense : €0.00 Mil (TTM As of Mar. 2026)
This article reports that Altimmune (FRA:3G0) had a Selling and Marketing Expense of €0.00 million for the trailing twelve months (TTM) ended March 2026. GuruFocus rates Altimmune with a GF Score of 28/100 and notes it has two warning signs. The article defines Selling and Marketing Expense as the aggregate total amount of expenses directly related to the marketing or selling of products or services and provides historical data and comparative analysis for premium members.
